GeneralBreaking NewsBreakingLatest News
Roche's Breast Cancer Pill Faces FDA Review, Promises 30% Fewer Relapses
Sentiment: NeutralHigh Priority
What Happened?
Roche's giredestrant is under review by the FDA for treating post-surgery and advanced breast cancer. The drug shows promise but faces evidence gaps and affordability concerns.
Key points
- Roche's giredestrant is still experimental and has not been approved by any regulator.
- The FDA has until November 30 to decide on its use after surgery and December 18 for advanced disease.
- Giredestrant has shown a 30% reduction in the risk of invasive recurrence compared to standard hormone therapy.
- The drug targets hormone receptor-positive and HER2-negative tumors.
- Roche estimates potential sales of up to $15 billion if approved.
- India reported about 2.37 lakh new breast cancer cases in 2024, the highest among all malignancies.
Key insights
- If approved, giredestrant could reshape treatment protocols for breast cancer patients.
- The drug's affordability will be crucial for access in low-income countries.
- Roche's success with giredestrant may influence future cancer drug development strategies.
Why it matters
The outcome of the FDA review could significantly impact breast cancer treatment options.
Tags
Entities
Roche· CompanyFDA· Organizationgiredestrant· Productbreast cancer· DiseaseIndia· CountryWorld Health Organization· Organization
Source
India Today
